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OBJECTIVE — Chlorinated persistent organic pollutants (POPs), endocrine disruptors
accumulated in adipose tissue, were associated with diabetes and metabolic syndrome.
Brominated ﬂame retardants (BFRs), such as polybrominated diphenyl ethers (PBDEs) or
polybrominated biphenyls (PBBs), are another class of POPs for which body burden is
increasing. Cross-sectional associations of serum concentrations of BFRs with diabetes and
metabolic syndrome were studied.
RESEARCH DESIGN AND METHODS — In the National Health and Nutrition Exam-
ination Survey 2003–2004, 1,367 adults were examined with respect to diabetes status. Five
PBDEs and one PBB were selected, detectable in 60% of participants. For the outcome meta-
bolic syndrome, we restricted the analysis to 637 participants with a morning fasting sample.
RESULTS — Comparedwithsubjectswithserumconcentrationsbelowthelimitofdetection,
prevalent diabetes had differing dose-response associations with serum concentrations of PBB-
153 and PBDE-153. Adjusted odds ratios across quartiles of serum concentrations for PBB-153
or PBDE-153 were 1.0, 0.7, 1.4, 1.6, and 1.9 (P for trend 0.01) and 1.0, 1.6, 2.6, 2.7, and 1.8
(P for quadratic term 0.01), respectively. PBB-153 was also positively associated with the
prevalence of metabolic syndrome with adjusted odds ratios of 1.0, 1.5, 3.1, 3.1, and 3.1 (P for
trend0.01). As in its association with diabetes, PBDE-153 showed an inverted U-shaped
association with metabolic syndrome.
CONCLUSIONS — Pending conﬁrmation in prospective studies, lipophilic xenobiotics, in-
cluding brominated POPs stored in adipose tissue, may be involved in the pathogenesis of
diabetes and metabolic syndrome.
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e have recently reported strong
cross-sectional associations of
serum concentrations of chlori-
nated persistent organic pollutants
(POPs) with diabetes (1,2). In addition to
diabetes, POPs were associated with most
components of metabolic syndrome, al-
though speciﬁc associations differed de-
pending on chemicals (3). Based on both
these epidemiological and previous ex-
perimental ﬁndings, we have proposed
that POPs stored in adipose tissue may
playakeyroleinthepathogenesisofmet-
abolic syndrome and type 2 diabetes (4).
As well-known endocrine disruptors,
their persistence in adipose tissue may
disturb normal function of lipid and glu-
cose metabolism in adipose tissue (4).
These lipophilic pollutants are a mix-
ture of several hundred chemicals with
similar properties, such as resistance to
biodegradation and bioaccumulation in
adiposetissue.Asidefromthechlorinated
POPs we studied before (dioxins, furans,
polychlorinated biphenyls [PCBs], or or-
ganochlorine pesticides), there are other
important subclasses of POPs. Among
them,chemicalsbelongingtobrominated
ﬂame retardants (BFRs) are of special in-
terest because of the recent marked in-
creaseinlevelsofpolybrominateddiphenyl
ethers (PBDEs), the most well-known class
ofBFR,inhumansaswellasintheenviron-
ment (5,6). PBDEs are extensively used in a
variety of consumer products, such as
home/ofﬁce furnishings and electronics, as
ﬂameretardants,andtheirbodyburdensin
North America are much higher than those
of Europeans (5).
Similar to chlorinated POPs, BFRs
bioaccumulate in adipose tissue in living
organisms and are suspected to be endo-
crine disruptors (7). Such lipophilic xe-
nobiotics in adipose tissue have been
suspected to disrupt hormonal signaling
in adipose tissue as endocrine disruptors
(8,9). They are chemically and toxicolog-
ically similar to PCBs, which were
strongly associated with hyperglycemia
and dyslipidemia in our previous studies
(5). Thus, BFRs may also be associated
with disturbance of lipid and glucose
metabolism.
Serum concentrations of biologically
important BFRs were measured in sub-
samplesoftheNationalHealthandExam-
ination Survey (NHANES) 2003–2004
(10). Our analyses were performed to in-
vestigate associations of prevalence of di-
abetes and metabolic syndrome with the
serum concentrations of BFRs.
RESEARCH DESIGN AND
METHODS— The NHANES, con-
ducted annually since 1999 by the Cen-
tersforDiseaseControlandPrevention,is
an ongoing survey designed to measure
the health and nutritional status of the
civilian noninstitutionalized U.S. popula-
tion (11). The surveys include household
interviews, standardized physical exami-
nations, and collection of medical histo-
ries and biologic specimens. Some of
these specimens were used to assess ex-
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Among 9,643 participants in the
NHANES 2003–2004, PBDEs and PBBs
were measured in serum from a random
one-third subsample of subjects aged
12 years.
The NHANES standardized home in-
terview was followed by a detailed physical
examinationinamobileevaluationclinicor
the participant’s home. Venous blood sam-
ples were collected and shipped weekly at
20°C.Waistcircumferencewasmeasured
at the high point of the iliac crest to the
nearest 0.1 cm at the end of normal expira-
tion. Serum triglyceride concentration was
measured enzymatically, and HDL choles-
terol concentration was analyzed using the
direct HDL cholesterol immunoassay
method. Up to four blood pressure mea-
surements were obtained from each partic-
ipant. To establish high blood pressure
status, we used the average of the last two
measurements of blood pressure for partic-
ipants who had three or four measure-
ments, the last measurement for
participants with only two measurements,
and the only measurement for participants
whohadonemeasurement.Plasmaglucose
wasmeasuredwithahexokinaseenzymatic
reference method. BFRs were measured by
high-resolution gas chromatography/high-
resolution mass spectrometry using isotope
dilution for quantiﬁcation. The BFRs were
reported on a lipid-adjusted basis using
concentrations of serum total cholesterol
and triglycerides. Among 11 BFRs mea-
sured in the NHANES, we selected ﬁve
PBDEs (PBDE-28, PBDE-47, PBDE-99,
PBDE-100, and PBDE-153) and one poly-
brominated biphenyl (PBB; PBB-153 se-
lected) for which at least 60% of study
subjects had concentrations more than the
limit of detection. A total of 1,367 study
participants aged 20 years with informa-
tion on serum concentrations of six BFRs
and fasting or random plasma glucose were
included for analysis. Participants were
considered to have diabetes if 1) their fast-
ing plasma glucose was 126 mg/dl, 2)
their nonfasting plasma glucose was 200
mg/dl, or 3) they were taking insulin or an
oral agent. Exclusion of nonfasting subjects
did not greatly change the estimates.
We deﬁned the metabolic syndrome
among fasting participants using the Na-
tional Cholesterol Education Program deﬁ-
nition. This deﬁnition required that the
participantsatisﬁedthreeormoreofthefol-
lowing ﬁve criteria: 1) waist circumference
102cminmenand88cminwomen,2)
fasting triglycerides 150 mg/dl, 3) HDL
cholesterol 40 mg/dl in men and 50
mg/dl in women, 4) blood pressure
130/85 mmHg or on antihypertensive
medication, and 5) fasting glucose 100
mg/dl or on antidiabetes medication.
Among 1,367 study subjects, 655 partici-
pants had information on fasting morning
samples suitable for measurement of trig-
lycerides and glucose. After excluding 18
subjectswithmissingdataonwaistcircum-
ference, the ﬁnal sample size was 637.
For each BFR, participants with serum
concentrations under levels of limit of de-
tection were regarded as the reference
group and those with detectable values cat-
egorizedbycutpointsatthe25th,50th,and
75thpercentiles.Logisticregressionmodels
were used to calculate multivariable-
adjustedoddratios.Variablesconsideredto
beconfoundersinthemultivariableanalysis
were age, sex, race/ethnicity, poverty in-
come ratio (the ratio of income to the fami-
ly’s poverty threshold; higher poverty
income ratio means wealthier), and BMI. In
the case of metabolic syndrome, we further
considered cigarette smoking (never,
former,orcurrent),cotinineconcentrations
(ng/ml), alcohol consumption (g/day), and
leisure-time physical activity (vigorous,
moderate, or none) as possible confound-
ers. In 149 participants, we substituted me-
dianvaluesoftheremainingparticipantsfor
missingpovertyincomeratio,BMI,cotinine
concentrations, or alcohol consumption.
Exclusion of these individuals did not ma-
terially alter any estimates. When associa-
tions did not look linear, we also ﬁt
quadratic models.
All statistical analyses were per-
formed with SAS 9.1 and SUDAAN 9.0.
Estimates of main results were calcu-
lated accounting for stratiﬁcation and
clustering, adjusting for age, race and
ethnicity, and poverty income ratio in-
stead of using sample weights. This ad-
justment has been regarded as a good
compromise between efﬁciency and
bias (12). As results were very similar
with SAS 9.1 and SUDAAN 9.0, we
present the results based on SAS 9.1.
RESULTS— The sample of 1,367 par-
ticipants included 47.3% men (53.3%
white).MeansSDforageandBMIwere
49.7  19.3 years and 28.3  5.9 kg/m
2,
respectively. In general, PBB-153 showed
different patterns of association with de-
mographic factors from PBDEs, except
PBDE-153 (Table 1). Among six BFRs,
only PBB-153 was positively associated
with age, while PBDEs showed no or in-
verse associations with age. In addition,
Table 1—Spearman correlation coefﬁcients between six BFRs with age, sex, race, poverty income ratio, and BMI (n  1,367)*
2,2,4,4,5,5-
hexabromophenyl
(PBB-153)
2,4,4-
tribromodiphenyl
ether (PBDE-28)
2,2,4,4-
tetrabromodiphenyl
ether (PBDE-47)
2,2,4,4,5-
pentabromodiphenyl
ether (PBDE-99)
2,2,4,4,6-
pentabromodiphenyl
ether (PBDE-100)
2,2,4,4,5,5-
hexabromodiphenyl
ether (PBDE-153)
Age 0.38† 0.04 0.03 0.05 0.07‡ 0.09†
Men 0.21† 0.02 0.03 0.03 0.04 0.15†
White race 0.13† 0.05 0.06‡ 0.08† 0.06‡ 0.03
Poverty income
ratio
0.06‡ 0.06‡ 0.06‡ 0.07† 0.07‡ 0.06‡
BMI 0.14† 0.03 0.002 0.03 0.02 0.16†
PBB-153 1 0.06 0.02 0.01 0.05 0.15†
PBDE-28 1 0.87† 0.76† 0.81† 0.55†
PBDE-47 1 0.90† 0.93† 0.62†
PBDE-99 1 0.85† 0.57†
PBDE-100 1 0.76†
PBDE-153 1
*Detectable values of each BFR were individually ranked to calculate correlation coefﬁcients; all undetectable values were ranked as 0. †P  0.01. ‡P  0.05.
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be white men and to have high socioeco-
nomicstatus.However,mostPBDEswere
not associated with sex, tended to be
higher among nonwhites, and tended to
be found in participants with low socio-
economic status. Both PBB-153 and
PBDE-153 were inversely associated with
BMI, while other PBDEs were not associ-
ated with BMI. Serum concentrations of
PBB-153 were not associated with those
of PBDEs, except for a weak correlation
with PBDE-153. All ﬁve PBDEs were
strongly and positively associated among
each other.
There were 156 diabetic case subjects
among 1,367 participants (prevalence
11.4%). The associations with diabetes
depended on BFR (Table 2). After adjust-
ing for age, sex, race, poverty income ra-
tio, and BMI, there was a signiﬁcant
positive association across ﬁve categories
of PBB-153 with diabetes prevalence,
with adjusted odds ratios of 1.0, 0.7, 1.4,
1.6, and 1.9 (P for trend 0.01). Among
ﬁve PBDEs, there was a nonlinear associ-
ation with diabetes across ﬁve categories
of serum concentrations of PBDE-153,
with adjusted odds ratios of 1.0, 1.6, 2.6,
2.7,and1.8(Pforquadraticterm0.01).
Although both PBDE-99 and PBDE-100
tended to show inverted U-shaped asso-
ciations similar with PBDE-153, they
failedtoreachstatisticalsigniﬁcance.Nei-
ther PBDE-28 nor PBDE-47 was associ-
ated with diabetes. Further adjustment
for waist circumference did not change
these results (data not shown).
Metabolic syndrome had a preva-
lence of 37.2% (237 of 637). There was
a positive association with the preva-
lence of metabolic syndrome across ﬁve
categories of serum PBB-153 concentra-
tion, with adjusted odds ratios of 1.0,
1.5, 3.1, 3.1, and 3.1 (P for trend
0.01) (Table 3). Similar to the associ-
ation with diabetes, PBDE-153 showed
an inverted U-shaped association with
metabolic syndrome, with adjusted
odds ratios of 1.0, 2.1, 2.5, 2.4, and 1.7
(P for quadratic term  0.02).
When we separately studied the ﬁve
components of metabolic syndrome,
PBB-153 was nonlinearly associated
with waist circumference, high triglyc-
erides, and low HDL cholesterol (P for
quadratic terms  0.09, 0.01, and
0.07, respectively). PBB-153 tended to
be positively associated with high fast-
ing glucose but did not reach statistical
signiﬁcance. However, PBB-153 was
signiﬁcantly associated with glycemia,
deﬁnedusingthehighercutoffpointfor
fasting glucose of 110 mg/dl instead
of100mg/dl(datanotshown).PBDE-
153 also showed an inverted U-shaped
association with high triglycerides (P
for quadratic term 0.01). Waist cir-
cumference or fasting glucose also
Table 2—Adjusted odds ratio (OR) and 95% CI of prevalent diabetes by category of six BFRs (n  1,367)*
Analyte
Not
detectable
Detectable P
trend‡
P
quadratic 25th† 25th to 50th 50th to 75th 75th
PBB-153
Median serum concentration
(ng/g of lipid)
— 1.2 2.3 3.8 13.1
Cases/n 11/166 16/306 39/303 41/292 49/300
Adjusted OR (95% CI) Referent 0.7 (0.3–1.6) 1.4 (0.7–3.0) 1.6 (0.8–3.5) 1.9 (0.9–4.0) 0.01 0.88
PBDE-28
Median serum concentration
(ng/g of lipid)
— 0.7 1.2 2.0 5.4
Cases/n 37/279 19/296 32/262 31/259 37/271
Adjusted OR (95% CI) Referent 0.5 (0.3–1.0) 1.2 (0.7–2.0) 0.9 (0.5–1.6) 0.8 (0.5–1.4) 0.93 0.97
PBDE-47
Median serum concentration
(ng/g of lipid)
— 6.5 13.7 28.2 73.3
Cases/n 2/36 43/333 34/333 40/332 37/333
Adjusted OR (95% CI) Referent 3.4 (0.8–15.7) 2.9 (0.6–13.5) 3.8 (0.8–17.4) 2.7 (0.6–12.5) 1.00 0.16
PBDE-99
Median serum concentration
(ng/g of lipid)
— 3.1 5.3 9.2 26.9
Cases/n 45/456 37/231 25/222 22/230 27/228
Adjusted OR (95% CI) Referent 2.0 (1.2–3.2) 1.5 (0.9–2.6) 1.2 (0.7–2.2) 1.3 (0.7–2.2) 0.57 0.06
PBDE-100
Median serum concentration
(ng/g of lipid)
— 1.4 2.8 5.6 16.8
Cases/n 10/94 37/330 37/305 35/322 37/316
Adjusted OR (95% CI) Referent 1.3 (0.6–2.8) 1.6 (0.7–3.5) 1.6 (0.7–3.5) 1.4 (0.6–3.0) 0.50 0.20
PBDE-153
Median serum concentration
(ng/g of lipid)
— 1.9 3.6 6.6 24.6
Cases/n 9/101 34/317 40/314 42/316 31/319
Adjusted OR (95% CI) Referent 1.6 (0.7–3.6) 2.6 (1.2–5.8) 2.7 (1.2–6.0) 1.8 (0.8–4.0) 0.15 0.01
*Adjusted for age, sex, race, poverty income ratio, and BMI. †Displayed is the median serum concentration in each category. ‡P trend was calculated without a
quadratic term in the model, while P quadratic was calculated including the linear term.
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none were signiﬁcant.
CONCLUSIONS — Inthisarticle,we
continued our examination of the rela-
tionships of POPs with diabetes and met-
abolic syndrome by studying BFRs.
AmongsixBFRs,PBB-153andPBDE-153
weresigniﬁcantlyassociatedwithbothdi-
abetesandmetabolicsyndrome,although
dose-response relationships did not ap-
pear to be the same between these two
chemicals. Thus, these data provide lim-
ited support for the proposition that be-
sides chlorinated POPs, other chemicals
with properties of persistence in adipose
tissue and endocrine disruptors may also
disturb glucose and lipid metabolism.
However, evidence in favor of this
conclusion is much stronger for chlori-
nated POPs (1–3) than for the bromi-
nated POPs, which were the focus of
this article. In our previous studies on
chlorinated POPs (1–3), most chemi-
cals belonging to the PCB and organo-
chlorine pesticide classes showed
strong associations with diabetes and
metabolic syndrome. Despite the chem-
ical and physical similarities among
PCBs, PBBs, or PBDEs, most chemicals
belonging to PBDEs, except PBDE-153,
were not clearly associated with diabe-
tes and metabolic syndrome.
In fact, there is an important differ-
ence in exposure route of PBDEs from
chlorinated POPs or PBBs. At ﬁrst, like
chlorinated POPs, diet was regarded as
a major pathway of exposure to PBDEs
becausetheyalsobioaccumulateinfood
chains (13). However, recent studies
discoveredthatthemainexposureroute
of PBDEs in the general population is
house dust, not diet, because it is used
asanadditivetoretardﬁreandﬂamesin
a variety of commercial and household
products (14). Humans are exposed to
PBDEs in house dust in direct inhala-
tion, ingestion, and dermal exposure
(5). Unlike PBDEs, PBBs were prohib-
ited in the U.S. in the 1970s after an
accidentalhumanexposureinMichigan
(15). Thus, their main exposure route
would be diet, which is similar to that
for chlorinated POPs (15). These differ-
ent exposure routes were reﬂected in
the correlations among serum BFR con-
centrations. Serum concentrations of
ﬁve chemicals belonging to PBDEs
showed very strong mutual correla-
tions, consistent with common expo-
sure sources. However, a serum PBB-
153 concentration showed, at most,
weakly positive associations in compar-
ison with associations with PBDEs. As
PBDEs were measured among the
NHANES participants in whom PCBs
were not measured, we could not exam-
ine the correlation between PCBs and
PBDEs. However, other studies with si-
Table 3—Adjusted odds ratio (OR) and 95% CI of prevalent metabolic syndrome by category of six BFRs (n  637)*
Analyte
Not
detectable
Detectable P
trend‡
P
quadratic 25th† 25th to 50th 50th to 75th 75th
PBB-153
Median serum concentration
(ng/g of lipid)
— 1.2 2.3 3.8 13.1
Cases/n 18/82 38/137 65/145 59/137 57/136
Adjusted OR (95% CI) Referent 1.5 (0.7–3.2) 3.1 (1.4–6.5) 3.1 (1.4–6.7) 3.1 (1.4–6.9) 0.01 0.07
PBDE-28
Median serum concentration
(ng/g of lipid)
— 0.7 1.2 2.0 5.4
Cases/n 50/142 41/149 44/107 50/116 52/123
Adjusted OR (95% CI) Referent 0.8 (0.4–1.5) 1.7 (0.9–3.1) 1.5 (0.8–2.8) 1.3 (0.7–2.4) 0.09 0.49
PBDE-47
Median serum concentration
(ng/g of lipid)
— 6.5 13.7 28.2 73.3
Cases/n 6/20 64/170 58/161 55/142 54/144
Adjusted OR (95% CI) Referent 1.1 (0.3–3.5) 0.8 (0.3–2.8) 1.2 (0.4–4.0) 1.1 (0.3–3.6) 0.70 0.72
PBDE-99
Median serum concentration
(ng/g of lipid)
— 3.1 5.3 9.2 26.9
Cases/n 82/223 50/122 34/99 37/88 34/105
Adjusted OR (95% CI) Referent 1.1 (0.7–2.0) 1.0 (0.6–1.8) 1.9 (1.0–3.5) 0.8 (0.5–1.5) 0.75 0.24
PBDE-100
Median serum concentration
(ng/g of lipid)
— 1.4 2.8 5.6 16.8
Cases/n 16/52 67/164 53/136 47/144 54/141
Adjusted OR (95% CI) Referent 1.8 (0.8–4.1) 1.5 (0.6–3.4) 1.6 (0.7–3.6) 1.7 (0.7–3.8) 0.68 0.61
PBDE-153
Median serum concentration
(ng/g of lipid)
— 1.9 3.6 6.6 24.6
Cases/n 19/52 65/162 54/133 52/143 47/147
Adjusted OR (95% CI) Referent 2.1 (1.0–4.6) 2.5 (1.1–5.6) 2.4 (1.0–5.3) 1.7 (0.7–3.8) 0.69 0.02
*Adjusted for age, sex, race, poverty income ratio, BMI, cigarette smoking, serum cotinine, alcohol consumption, and exercise. †Displayed is the median serum
concentration in each category. ‡P trend was calculated without a quadratic term in the model, while P quadratic was calculated including the linear term.
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association between these two chemi-
cals (16).
Therefore, serum concentrations of
chlorinated POPs or PBBs, with expo-
sureprimarilythroughfood,mayreﬂect
a cumulative lifetime dose of exposure.
However, serum concentrations of PBDEs
maybeamixtureofmorerecentexposure
to indoor pollution and cumulative low
exposure to diet. These considerations
appeared to be well reﬂected in the asso-
ciations with age. PBBs and chlorinated
POPs (1–3) were strongly associated with
age, while most PBDEs were not, or even
inversely, associated with age. Unlike tra-
ditional toxicological effects due to acute
high-dose exposure, disturbance of glu-
cose and lipid metabolism due to POPs in
adipose tissue as endocrine disruptors
may require long-term exposure. Thus,
we think that serum concentrations of
PBDEs may not reﬂect a biologically im-
portant long-term dose. Furthermore,
toxicological studies have shown that dif-
ferent exposure routes led to different
pharmacokineticsintermsofuptake,dis-
tribution, and elimination (17).
However, PBDE-153 tended to stand
out from other PBDEs in several ways.
Even though PBDE-153 showed an in-
verse association with age, opposite to
that of PBB-153, serum concentrations of
PBDE-153, compared with other PBDEs,
were more positively correlated with
those of PBB-153. In addition, both the
higher concentrations in men and the in-
verseassociationwithBMIweresimilarto
those of PBB-153 but different from other
PBDEs. It may be that PBDE-153 has dif-
ferent pharmacokinetics from other
PBDEs.
The signiﬁcant associations of PBB-
153 and PBDE-153 need further discus-
sion in relation to their differing dose-
response curves. Interestingly, in our
previous studies (1–3), we also found
nonlinear dose-response relations of
PCBs with various outcomes, including
plateaus or inverted U-shaped associa-
tions. Among various subclasses of
POPs, PCBs are the subclass that has
most similar structures to BFRs (5).
Thus, a similar dose-response curve be-
tween PCBs and BFRs may be biologi-
cally plausible. In fact, in addition to
PCBs, most chlorinated POPs showed
an association that was much steeper
across lower background concentra-
tions than across higher background
concentrations. Although a linear dose-
response relation is generally regarded
by epidemiologists as a criterion for
causality, the possibility of inverted U-
shaped associations with endocrine dis-
ruptors has been suggested by some
experimental studies (a strong effect
across low doses but a weakened or no
effect at high doses) (18). Although re-
searchers cautioned that low-dose ef-
fects cannot be extrapolated from
animal studies to humans (19), our
ﬁndings on PCBs, PBBs, or PBDEs sug-
gest that this concept might also apply
in the human body.
This nonlinear dose-response curve
may explain previous epidemiological
ﬁndingsintheMichigancohortwithac-
cidental high exposure to PBBs (20). In
fact, this prospective cohort study did
not show any association between PBB
concentrations and incident diabetes.
However, serum concentrations of the
reference group in the Michigan cohort
were already much higher than those of
current participants. No association in
subjects with high exposure to POPs
but strong associations in subjects with
background exposure to POPs were
similarly observed with chlorinated
POPs (21).
Even though it is still unclear what
biological mechanism is involved in the
association of POPs with diabetes and
metabolic syndrome, the potential of xe-
nobioticstodisruptglucoseandlipidme-
tabolism in mammals is a well-developed
theory in toxicology (8). Indeed, many of
the early toxicity responses in animal
studies with a range of pollutants note
glucosuria, dyslipidemia, increased glu-
coneogenesis, and fatty liver (8). Further-
more, dioxin-like compounds exert their
effects through binding to the aryl-
hydrocarbon receptor, which is thought
Table4—Adjustedoddsratio(OR)and95%CIofprevalenceofﬁvecomponentsofmetabolicsyndromebycategoryofPBB-153andPBDE-153*
Not
detectable
Detectable P
trend‡
P
quadratic 25th† 25th to 50th 50th to 75th 75th
Waist circumference 102 cm in
men or 88 cm in women
PBB-153 Referent 1.3 (0.4–4.1) 3.5 (1.1–11.7) 2.4 (0.7–8.1) 2.1 (0.6–7.2) 0.28 0.09
PBDE-153 Referent 2.4 (0.6–9.3) 2.2 (0.6–8.6) 1.9 (0.5–7.4) 2.8 (0.7–10.8) 0.40 0.78
Triglycerides 1.7 mmol/l
PBB-153 Referent 3.2 (1.6–6.5) 4.2 (2.1–8.7) 3.7 (1.7–7.8) 3.8 (1.8–8.0) 0.01 0.01
PBDE-153 Referent 4.3 (1.9–9.5) 3.5 (1.5–7.9) 3.7 (1.6–8.4) 3.2 (1.4–7.5) 0.35 0.01
HDL cholesterol 1.1 mmol/l in
men or 1.4 mmol/l in
women
PBB-153 Referent 2.1 (1.1–4.2) 2.4 (1.2–4.9) 2.5 (1.2–5.2) 2.5 (1.2–5.2) 0.05 0.07
PBDE-153 Referent 0.9 (0.4–1.9) 1.6 (0.8–3.4) 1.1 (0.5–2.3) 1.1 (0.5–2.3) 0.79 0.29
Blood pressure 130/85 mmHg
PBB-153 Referent 0.7 (0.3–1.4) 1.3 (0.6–2.5) 0.8 (0.4–1.7) 0.7 (0.3–1.4) 0.47 0.33
PBDE-153 Referent 1.4 (0.7–2.9) 1.6 (0.7–2.4) 1.5 (0.7–3.3) 1.3 (0.6–2.9) 0.65 0.23
Fasting glucose 5.6 mmol/l
PBB-153 Referent 1.0 (0.5–2.0) 1.2 (0.6–2.4) 1.2 (0.6–2.4) 1.6 (0.8–3.2) 0.11 0.63
PBDE-153 Referent 1.8 (0.9–3.8) 1.4 (0.6–2.9) 1.5 (0.7–3.1) 1.2 (0.6–2.5) 0.51 0.24
*Adjusted for age, sex, race, poverty income ratio, BMI, cigarette smoking, serum cotinine, alcohol consumption, and exercise. †The median serum concentration
in each category is displayed. ‡P trend was calculated without a quadratic term in the model, while P quadratic was calculated including the linear term.
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activated receptors (9).
The inverse association of PBB-153
and PBDE-153 with BMI was interesting.
In fact, both of these POPs showed posi-
tiveassociationswithwaistcircumference
after adjusting for BMI. In our previous
studies (1–3), PCBs were also inversely
associated with BMI but positively associ-
ated with waist circumference, while
other chlorinated POPs were weakly and
positively associated with both BMI and
waist circumference. The exposure to
POPs may affect visceral adipose tissue
differentlythansubcutaneousadiposetis-
sue,andtheseeffectsmaydependonPOP
subclass. Furthermore, even though
POPs are generally observed to be posi-
tively associated with obesity, associa-
tions between POPs and obesity would
not be simple. For example, a high intake
of fatty food is related to both a high POP
exposureandobesity.Onthecontrary,an
increase of adipose tissue mass itself di-
lutes the concentrations of POPs. Fur-
thermore, some experimental studies
have reported that the exposure to endo-
crine disruptors itself can induce obesity
(22). As these mechanisms do not all act
in the same direction, the associations be-
tween POPs and obesity may be diverse.
This study has several limitations.
First, the current ﬁndings should be in-
terpreted with caution due to the cross-
sectional nature of this study. Even
though our results are biologically plausi-
ble because some PBDEs are reported to
causethedisturbanceofglucoseandlipid
metabolism in adipose tissue (7), we
could not exclude the possibility that
changes in metabolic state due to disease
could have created the associations we
observed. Second, BFRs were not mea-
sured in the same population as chlori-
nated POPs in the NHANES, so we
could not simultaneously consider the
effect of chlorinated POPs. There may
beapossibilityofsynergisticeffectsthat
multiple POPs reinforce each other’s
toxicity in the general population, as we
discussed previously (21). Third, infer-
enceshouldbemadecautiouslyinlightof
the multiple comparisons intrinsic in this
investigation.
Along with our previous ﬁndings on
chlorinated POPs, our current study sug-
gests that the background exposure to
somebrominatedPOPsmaybecloselyre-
lated to disturbance of glucose and lipid
metabolism in the general population.
ProspectivestudiesoftherelationofPOPs
with diabetes and metabolic syndrome
are needed because both the exposure
and the disease have substantial preva-
lenceandthepublichealthsigniﬁcanceof
such a relation could be marked.
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